Front Oncol: Domestic multi-center evaluation of the efficacy of Regorafenib (regorafenib) third-line or above in the treatment of patients with refractory metastatic colorectal cancer (mCRC)

Recently, a domestic multi-center team published a study in the journal Frontiers in Oncology, mainly to evaluate the efficacy of Regorafenib (regorafenib) third-line or above in the treatment of patients with refractory metastatic colorectal cancer (mCRC)

The study included patients with refractory metastatic colorectal cancer (mCRC) from 4 centers in China between February 1, 2018 and June 31, 2021, divided into 3 groups: regorafenib monotherapy, regorafenib Combined chemotherapy group and regorafenib combined with anti-PD-1 treatment group

A total of 177 patients were included in this study, of which 116 (65.

The median follow-up time was 9.

Median PFS was longer in the regorafenib plus immunization group than in the monotherapy group (3.

Patients who started treatment at 120 mg had longer PFS and OS compared to those who started treatment at 80 mg (PFS: mPFS: 3.

All 177 patients were assessed for toxicity

In conclusion, the study showed that in patients with refractory mCRC, regorafenib combined with immunotherapy had better PFS, while combined with chemotherapy had better OS

Xu D, Liu Y, Tang W, Xu L, Liu T, Jiang Y, Zhou S, Qin X, Li J, Zhao J, Ye L, Chang W and Xu J (2022) Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi -Center Retrospective Study.